An Open-Label, Randomized, Four-Period, Three-Block, Pharmacokinetic Study of Three Formulations of Decitabine/Tetrahydrouridine (THU) Combination Modified Release Capsules in Healthy Adults Under Fasting and Fed Conditions
Latest Information Update: 24 Jan 2020
At a glance
- Drugs Decitabine/tetrahydrouridine (Primary)
- Indications Beta-thalassaemia; Cancer; Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors EpiDestiny
Most Recent Events
- 21 Jan 2020 Status changed from recruiting to completed.
- 02 Oct 2019 Status changed from not yet recruiting to recruiting.
- 13 Sep 2019 New trial record